These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8904619)
1. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Wan J; Xia H; He N; Lu YQ; Zhou HH Br J Clin Pharmacol; 1996 Oct; 42(4):471-4. PubMed ID: 8904619 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765 [TBL] [Abstract][Full Text] [Related]
3. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Zhang YA; Reviriego J; Lou YQ; Sjöqvist F; Bertilsson L Clin Pharmacol Ther; 1990 Nov; 48(5):496-502. PubMed ID: 2225709 [TBL] [Abstract][Full Text] [Related]
4. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148 [TBL] [Abstract][Full Text] [Related]
5. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Sohn DR; Kusaka M; Ishizaki T; Shin SG; Jang IJ; Shin JG; Chiba K Clin Pharmacol Ther; 1992 Aug; 52(2):160-9. PubMed ID: 1505151 [TBL] [Abstract][Full Text] [Related]
6. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Caraco Y; Tateishi T; Wood AJ Clin Pharmacol Ther; 1995 Jul; 58(1):62-72. PubMed ID: 7628184 [TBL] [Abstract][Full Text] [Related]
7. Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Qin XP; Xie HG; Wang W; He N; Huang SL; Xu ZH; Ou-Yang DS; Wang YJ; Zhou HH Clin Pharmacol Ther; 1999 Dec; 66(6):642-6. PubMed ID: 10613621 [TBL] [Abstract][Full Text] [Related]
8. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668 [TBL] [Abstract][Full Text] [Related]
9. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. Madsen H; Nielsen KK; Brøsen K Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151 [TBL] [Abstract][Full Text] [Related]
10. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510 [TBL] [Abstract][Full Text] [Related]
11. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Andersson T; Regårdh CG; Lou YC; Zhang Y; Dahl ML; Bertilsson L Pharmacogenetics; 1992 Feb; 2(1):25-31. PubMed ID: 1302040 [TBL] [Abstract][Full Text] [Related]
12. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407 [TBL] [Abstract][Full Text] [Related]
13. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Brøsen K; de Morais SM; Meyer UA; Goldstein JA Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772 [TBL] [Abstract][Full Text] [Related]
14. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Sohn DR; Kwon JT; Kim HK; Ishizaki T Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419 [TBL] [Abstract][Full Text] [Related]
15. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632 [TBL] [Abstract][Full Text] [Related]
16. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. Yao TW; Zeng S; Wang TW; Chen SQ Biomed Chromatogr; 2001 Feb; 15(1):9-13. PubMed ID: 11180294 [TBL] [Abstract][Full Text] [Related]
17. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476 [TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Jurima-Romet M; Goldstein JA; LeBelle M; Aubin RA; Foster BC; Walop W; Rode A Pharmacogenetics; 1996 Aug; 6(4):329-39. PubMed ID: 8873219 [TBL] [Abstract][Full Text] [Related]
19. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208 [TBL] [Abstract][Full Text] [Related]
20. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population. Xie HG Life Sci; 2000 Feb; 66(14):PL175-81. PubMed ID: 10755474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]